Please assess the completion status of the following clinical trial:

Trial Title: Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, ages 10-18 years.~2. Female patients of menarche must be using a medically accepted means of contraception (e.g. oral contraceptives, Depo-Provera, abstinence).~3. Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation.~4. Patients must have a diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) bipolar disorder, type I and currently display an acute manic or mixed episode as determined by K-SADS (Geller et al 2000).~5. Patients must have a baseline (day 0) Young Mania Rating Scale score of at least 16.~6. Subjects should be fluent in English.~Exclusion Criteria:~1. Female patients who are either pregnant or lactating.~2. Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions.~3. Any history of current or past diabetes that has been treated with pharmacological intervention.~4. Neurological disorders including epilepsy, stroke, or severe head trauma.~5. Clinically significant laboratory abnormalities (\> 3 times upper limit of normal), on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid profile, fasting glucose, urinalysis, or thyroid indices. Clinically abnormal ECG.~6. Manic or mixed episode due to a general medical condition or substance-induced mania (DSM-IV-TR).~7. Mental retardation (IQ \<70).~8. History of hypersensitivity to or intolerance of olanzapine or topiramate.~9. Prior history of olanzapine or topiramate non-response or allergic reaction.~10. DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months.~11. Judged clinically to be at suicidal risk (defined as having active suicidal ideation, intent or plan, or a serious suicide attempt within 30 days, or a baseline Children's Depression Rating Scale suicide score of \>3).~12. Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0.~13. Treatment with concurrent mood stabilizers or anticonvulsants, benzodiazepines (except as described below), psychostimulants, guanethidine, or guanadrel, or antidepressants.~14. Schizophrenia or other psychotic disorders (including schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified) as defined in the DSM-IV.~15. Major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Topiramate Group (Type: EXPERIMENTAL): Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.
- Placebo Group (Type: PLACEBO_COMPARATOR): Sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).